Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc. (AKBA) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
akba · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$4.00
+336.8% upside
Low
$4.00
Median: $4 · Last Close: $0.92
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BearAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.87 | ↓ 5.00% |
1-day model range: $0.86–$0.88. Peak: $0.88 (-5.00%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | +9.8% |
| 2028 | $1 | +15.3% |
| 2029 | $1 | +18.1% |
| 2030 | $1 | +19.5% |
| 2031 | — | +20.3% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AKBA · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-04-07 | BTIG | Maintains | Buy→Buy |
| 2026-02-25 | BTIG | Maintains | Buy→Buy |
| 2026-02-06 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-02-06 | Piper Sandler | Maintains | Overweight→Overweight |
| 2025-12-02 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-12-02 | BTIG | Maintains | Buy→Buy |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-10-29 | BTIG | Maintains | Buy→Buy |
| 2025-04-04 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-03-14 | Piper Sandler | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Akebia Therapeutics, Inc. (AKBA) stock. Of the recent 62 rating actions, 3 were upgrades and 5 were downgrades. 11 analysts currently cover AKBA.
Analyst Recommendation Trends
AKBA analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$207M
↑ 2.1% YoY
Revenue Next Year
$160M
↓ 22.7% YoY
EPS This Year
$-0.14
EPS Next Year
$-0.23
↑ 62.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast AKBA EPS of $-0.14 for the current fiscal year, based on estimates from 3 analysts. The AKBA revenue forecast is $207M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AKBA stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AKBA price target is $4.00 (+336.8% upside), with an analyst consensus of Buy.
The AKBA short-term stock prediction for tomorrow is $0.87 (-5.00%). The AKBA stock price prediction for 2027 estimates an average of $1. The AKBA stock prediction for 2030 projects a range of $1–$1.
Akebia Therapeutics, Inc. trades on NASDAQ under the ticker AKBA. The AKBA stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.
Frequently asked questions
AKBA forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month AKBA price target is $4.00, with a high forecast of $4.00 and a low of $4.00. The median price target is shown in the chart above when available. This implies +336.8% potential upside from the current price of $0.92.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.